EP0557333A1 - Inhalation device. - Google Patents

Inhalation device.

Info

Publication number
EP0557333A1
EP0557333A1 EP91919636A EP91919636A EP0557333A1 EP 0557333 A1 EP0557333 A1 EP 0557333A1 EP 91919636 A EP91919636 A EP 91919636A EP 91919636 A EP91919636 A EP 91919636A EP 0557333 A1 EP0557333 A1 EP 0557333A1
Authority
EP
European Patent Office
Prior art keywords
vane
movement
activator component
dispensing
catch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP91919636A
Other languages
German (de)
French (fr)
Other versions
EP0557333B1 (en
Inventor
Anthony Charles Lammond T Wass
Brian Robert Law
Eric Arthur Shepherds Clo Baum
Peter David Kingsmead A Hodson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of EP0557333A1 publication Critical patent/EP0557333A1/en
Application granted granted Critical
Publication of EP0557333B1 publication Critical patent/EP0557333B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0096—Hindering inhalation before activation of the dispenser

Definitions

  • INHALATION DEVICE This invention relates to inhalation activatable devices for the administration of medicaments for inhalation therapy.
  • Inhalation activatable dispensers for use with aerosol container assemblies are known, their general purpose being to afford proper co-ordination of the dispensing of a dose of medicament with the inhalation of the patient thereby allowing the maximum proportion of the dose of medicament to be drawn into the patient's bronchial passages. Examples of such dispensers are described in British Patent Specification Nos. 1,269,554, 1,335,378, 1,392,192 and 2,061,116 and United States Patent Nos.
  • European Patent No. 147028 discloses an inhalation activatable dispenser for use with an aerosol container in which a latch mechanism releasing vane is pivotally mounted in an air passage between an aerosol outlet valve and a mouthpiece, which latch mechanism cannot be released if..force to activate the dispenser is not applied before a patient inhales.
  • the dispenser generally comprises a housing having a mouthpiece and an air passage therethrough terminating at the mouthpiece, the housing being adapted to receive an aerosol container and having a support block with a socket adapted to receive the stem of the valve of the aerosol container and a through orifice communicating between the socket and the air passage, and latch means having parts movable between an engaged position in which movement of the container and the support block toward each other upon the application of a force to bias the container and the support block toward each other is prevented and a release position in which movement of the container and the support block toward each other in response to said force is permitted causing the stem to move to its inner discharge position, the latch means comprising a vane mounted on the housing in the air passageway between the orifice and the mouthpiece for movement toward the mouthpiece under the influence of inhalation through the mouthpiece to release the latch means in which the vane moves toward the mouthpiece from a blocking to a non-blocking position with respect to the passageway in response to inhaling at the mouthpiece and releases the latch means only during the application
  • PCT/US90/02412 discloses a dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that.pa ⁇ :t__c__les of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow.
  • the dry powder inhaler is capable of delivering multiple, uniform doses of a medicament to a patient.
  • the device is simple to operate and does not require the patient to insert capsules of medicament or rely upon a separate reservoir of medicament in order to load the device for use.
  • the medicament is generally preloaded on an elongate carrier, sections of which are sequentially exposed in the chamber for dispensing the medicament.
  • the elongate carrier is preferably in the form of a tape having an array of depressions or microdimples holding micronised medicament and may be conveniently loaded on a spool (in a similar manner to a photographic film) or in a cassette (in a similar manner to an audio cassette) .
  • a preferred carrier is disclosed in European Patent Publication No. 0455463.
  • the device includes means for advancing the elongate carrier through the chamber to sequentially expose areas of the carrier for release of medicament during inhalation by the patient.
  • the means for advancement may take a variety of forms depending upon the type of elongate carrier and whether the exposed areas of carrier are to be retained within the device.
  • tapes webs and belts may include a series of apertures which are engaged by one or more sprocketed guide wheels or rollers in a similar manner to a camera or printer.
  • the carrier may be wound on a take-up spool, rotation of the spool directly or via a drive belt causing the carrier to advance.
  • the device may also include means for tensioning or otherwise maintaining the exposed area of the carrier within the chamber during inhalation by the patient.
  • the elongate carrier may be advanced into the chamber prior to inhalation by the patient or the carrier may be advanced into the aerosolisation chamber during inhalation to protect the powdered medicament from premature exposure.
  • the elongate carrier is stored in a cassette both before and after exposure.
  • the cassette may comprise one or preferably two spools together with idlers or other rollers and include an exposure frame positioned within the chamber, through which the carrier is advanced.
  • the cassette may be removable to allow the device to be recharged with a new cassette.
  • spent carrier may be advanced to the exterior of the device through a slot in the housing whereupon disposal may be effected by the patient, optionally with the aid of a cutting edge.
  • This arrangement is particularly suitable for a tape carrier which has transverse perforations to facilitate tearing off spent carrier.
  • the device preferably additionally comprises means for releasing medicament of respirable size from the exposed area of carrier independent of the patients' inspiratory effort.
  • the medicament release means overcomes the binding of the medicament particles to the carrier by mechanical effort e.g. impaction, vibrations, gas flow etc. or electrostatically.
  • the means for releasing medicament from the carrier during inhalation is preferably triggered in response to the patient inhaling in order to avoid the patient having to synchronise inhalation and actuation of the release mechanism.
  • Airflow detection may conveniently be accomplished by.means of a movable vane positioned within the chamber or patient port, motion of the vane causing actuation of the release mechanism.
  • Such a vane may also be constructed to prevent a patient exhaling through the device and/or to prevent exhaled air from reaching the stored carrier thereby avoiding any problems associated with moisture.
  • the present invention provides an improved triggering mechanism which is suitable for use in such an inhalation device and may also be employed in other dry powder or pressurised aerosol inhalation devices.
  • an inhalation device for -administration of aerosolised medicament to the respiratory system of a patient
  • a housing defining a patient port in the form of a mouthpiece or nasal adaptor and an air inlet
  • the housing containing means for dispensing a dose of aerosolised medicament
  • an inhalation-activatable triggering mechanism for initiating the dispensing means
  • reset means in which the triggering mechanism comprises a vane mounted for pivotal movement between closed and open positions, the vane being positioned such that inhalation through the patient port generates an air flow from the air inlet to the patient port causing pivotal movement of the vane, and an activator component movable between a restrained position and a dispensing position which movement causes dispensing of medicament from the dispensing means, the activator component being biased towards its dispensing position
  • the triggering mechanism being constructed and arranged such that: a) when the activator component is in the restrained position and the vane is in the closed position the activator component is held in its rest
  • the activator component is arranged to move pivotally between its restrain-id position and. its dispensing position, but it may alternatively be arranged to move reciprocally, linearly or in some other fashion.
  • the invention provides a triggering mechanism for actuating an inhaler device which obviates the need for handling co-ordination by the patient and actuates at low flow-rates, e.g., 30 litres per minute, within the capabilities of most asthma sufferers.
  • the components of the triggering mechanism are arranged such that they may mechanically interengage during the reset cycle thus by simply returning the activator component to its restrained position it is positively ensured that the other components are returned to their respective positions ready for the next triggering sequence.
  • the vane is conveniently positioned within the patient port of the inhalation device and may be arranged such that it may be wholly or partially returned from its open to its closed position prior to the reset cycle providing it is then positively engaged by a component of the triggering- mechanism as the. mechanism is reset.
  • This freedom of movement of the vane which may take place under the influence of gravity should the patient's inhalation falter or which may take place should the patient exhale through the patient port, allows the mouthpiece to be closed by the vane preventing contaminants entering the housing prior to resetting the triggering mechanism.
  • the vane pivot point is ordinarily positioned towards one end of the vane.
  • the triggering mechanism is particularly suitable for use in the inhalation devices of International
  • the triggering mechanism may readily*-_e- employed in.-other dry powder and pressurised aerosol devices which utilise a biased activator component.
  • the triggering mechanism may simply comprise a vane and activator component.
  • the vane comprises blocking and reset surfaces positioned at an end of the vane near the pivot point, e.g. by providing a pair of projections or arms on the vane, such that: a) when the activator component is in the restrained position and the vane is in the closed position the blocking surface mechanically engages the activator component preventing movement " of the activator component from its restrained position.
  • a three component triggering mechanism may comprise a vane, catch and activator component, the catch being pivotally mounted for movement between a blocking position in which it mechanically blocks movement of the activator component from its restrained position and a release position in which it allows movement of the activator component to its dispensing position, the catch and vane each having a respective engagable end which allows movement transfer therebetween, the catch having a second end having a blocking -surface which engages the activator component in its restrained position and a reset surface which is engaged by the activator component during movement from its dispensing to its restrained position under the influence of the reset means thereby causing movement of the catch to its blocking position and vane to its closed position.
  • a four component triggering mechanism may comprise a vane, rocker, catch and activator component, the catch being pivotally mounted for movement between a blocking position in which it mechanically blocks movement of the activator component from its restrained position and a release position in which it allows movement of the activator component to its.dispensing position, the rocker being mounted for pivotal movement and having one end engagable with one end of the vane to allow movement transfer therebetween and a second end engagable with the catch to allow movement transfer therebetween, the catch having a blocking surface which engages the activator component in its restrained position and a reset surface which is engaged by the activator component during movement from its dispensing to its restrained position under the influence of the reset means thereby causing movement of the catch to its blocking position, and movement of the rocker and thereby movement of the vane to its closed position.
  • the reset means for the triggering mechanism preferably acts directly on the activator component and moves it against its biasing;,means back to its restrained position.
  • the reset means may conveniently take the form of a projection on a hinged cover for the mouthpiece such that the inhalation device is reset when the cover is closed after the patient has used the device.
  • Figures 1 to 10 represent a cross-section through an inhaler in accordance with the invention illustrating the various stages of operation
  • Figures 11 and 12 represent cross-sections through a second inhaler in accordance with the invention
  • Figures 13(a) to 13(c) represent diagrams of a further triggering mechanism for use in the invention
  • Figures 14(a) to 14(c) represent partial cross- sections of an inhaler in accordance with the invention having a pressurised aerosol container
  • Figures 15(a) and 15(b) represent diagrams of the triggering and reset cycles of a two component triggering mechanism.
  • the inhaler of Figures 1 to 10 is of a type disclosed in International Publication No. WO90/13328, the medicament being carried on a tape contained within a removable cassette.
  • FIGS. l to 5 of the accompanying drawings illustrate a section- through an inhaler with the cassette removed.
  • the inhaler comprises a housing (2) , a movable cover (4) and a patient port (6) in the form of a mouthpiece.
  • the means for releasing medicament is in the form of an activator generally shown at (8) which comprises an impactor head (11 * ) for striking the elongate carrier, the impactor head being attached to a stem (12) which is mounted for movement and rotation about point (14) .
  • An impactor spring (15) provides a bias to move the activator to its dispensing position and is secured to the stem (12) and has a roller (16) at one end thereof.
  • the activator is held in a restrained position by.
  • a catch (18) which has a blocking surface (20) in the form of a roller engaging the impactor head (10) of the activator.
  • the catch (18) is mounted for pivotal movement about point (22) and has an arm (24) engaged by rocker (26) .
  • the rocker (26) is mounted for pivotal movement about point (28) .
  • the means for detecting patient inspiration comprises a vane (30) positioned within the mouthpiece (6) .
  • the vane (30) is mounted for pivotal movement about point (32) and includes a projection (34) which engages the surface (35) of the rocker (26) .
  • Figure 1 shows the device with the cover closed and the components restrained. Opening of the cover ( Figure 2) causes pivotal movement of cam (36) acting on roller (16) thereby imparting tension to the impactor spring (15) . Movement of the impactor head (10) is prevented by the catch (18) .
  • the vane (30) pivots as shown in the direction of the arrow. Pivotal movement of the vane (30) in turn causes pivotal movement of the rocker (26) and pivotal movement of the catch (18) as shown in the direction of the arrows, causing the roller (20) to lift clear of the impactor head (10) thereby allowing the activator to move in the direction of the arrow (A) ( Figure 3) and the impactor head (10) to strike the elongate carrier.
  • the vane (30) is lifted to the top of the passage of the mouthpiece during inhalation.
  • the end of the vane (30) includes a curved portion (31) which extends in to the potential pathway for exhaled air, thereby ensuring the vane (30) will snap shut immediately, should the patient exhale through the mouthpiece (6) ( Figure 4) .
  • the vane may be straight, but a curve (not shown) in the roof of the mouthpiece may ensure that the end of the vane extends into the potential pathway for exhaled air.
  • FIG. 5 illustrates drive gear (40) which is connected to the cover (4) for rotation during opening of the cover (4) .
  • the drive gear (40) drives idler gear (42).
  • the cassette 44) containing the elongate carrier, is inserted in the device and may be retained by a pivoted catch (46) .
  • the cassette (44) comprises a housing (48) ( Figure 7) and contains spools (50 and 52) , the elongate carrier (54) being wound on spool (50) and extending via rollers (56 and 58) to spool (52) .
  • a drive belt (60) passes round idler rollers (62) and contacts the carrier (54) on spool (50) , throughout its entire length around the rollers (56 and 58) and on spool (52) .
  • the drive belt also extends around driven roller (64) .
  • the driven roller (64) includes a non-return ratchet generally shown at (66) and also includes a similar drive ratchet (not shown) mounted lower on the shaft.
  • Figure 8 illustrates the inhaler during inhalation through the mouthpiece.
  • the impactor head (10) comprises a raised impactor surface (11) which strikes the drive belt (60) which is in contact with the tape (54) thereby imparting sufficient energy to the tape (54) to release the powdered medicament in to the air stream formed by the patient's inhalation.
  • Figure 9 illustrates the movement of the various components during the reset cycle which is achieved by closing of the cover.
  • the activator (8.) is moved to its restrained position by reset projection (68) mounted on the inside of the cover.
  • the activator (8) is returned towards its restrained position by the reset projection (68) it engages the reset surface (78) of the catch (18) causing pivotal movement of the catch (18) in the direction of the arrows.
  • the arm (24) of the catch (18) engages the rocker (26) causing pivotal movement of the rocker (26) in the direction of the arrows. Movement of the rocker (26) causes engagement between the surface (35) and the projection (34) on the vane (30) .
  • the point during the reset cycle at which this engagement will "'-occur depends upon the position of the vane when the reset cycle is commenced. If the vane is in its opened position the rocker will immediately engage the vane but if the vane is in the closed position, e.g. if the patient has exhaled through the mouthpiece, engagement of the rocker and vane will not occur until the end of the reset cycle. Engagement will occur part way through the reset cycle if the vane is in an intermediate position.
  • the mouthpiece (6) may be integrally formed with the housing or may be removable for cleaning purposes.
  • Figure 10 of the drawings illustrates a removable mouthpiece (6) .
  • the mouthpiece comprises a peg (70) which is engaged within slot (72) in the housing of the inhaler.
  • the peg (70) may be disengaged from the slot for complete removal of the mouthpiece (6) .
  • the mouthpiece (6) additionally comprises a retaining clip (74) which engages with the sides of aperture (76) formed on the housing of the inhaler.
  • Figures 11 and 12 illustrate an inhaler similar to that of Figures 1 to 10 having a modified triggering mechanism. Like numerals in these Figures represent like components in Figures 1 to 10.
  • the rocker (26) comprises an arm (82) which engages the arm (24) of the catch (18) during the triggering and reset cycles.
  • the catch comprises a blocking arm (86) which engages the activator (8) in its restrained position and reset arm (88) which engages the activator (8) during the reset cycle.
  • the activator (8) is biased towards its dispensing position by spring (90) .
  • Figure 11 shows the inhaler at the onset of inhalation through the mouthpiece (6) with the vane (30) lifting causing pivotal movement of the rocker (26) and catch (18) in the direction of the arrows.
  • Figure 12 shows the inhaler dispensing the medicament; the vane (30) has lifted to its open position causing sufficient movement of the rocker (26) and catch (18) such that the blocking arm (86) of the catch (18) disengages the activator (8) allowing the activator (8) to pivot to its dispensing position under the influence of spring- (90) .
  • the impactcr head (92) carried on the activator (8) strikes the elongate carrier to dispense powdered medicament into the airflow for inhalation by the patient.
  • reset projection (68) pushes the activator (8) back to its restrained position thereby tensioning spring (90) .
  • the activator engages reset arm (88) of the catch (18) causing pivotal movement of the catch (18) .
  • the arm (24) of the catch (18) engages arm (82) of the rocker (26) causing pivotal movement of the rocker (26) .
  • Surface (35) of the rocker engages projection (34) of the vane (30) to complete vane closure thereby resetting the triggering mechanism.
  • the reset projection preferably moves out of contact with the activator (8) and is positioned within recess (94) formed in the activator (8) to ensure that the activator (8) is restrained by the catch (18) with no strain on the cover (4) .
  • This arrangement also allows the cover (4) to be fully closed.
  • the rocker (26) is arranged such that it is unable to rotate so far clockwise as to no longer be engagable by the catch (18) and such that the surface (35) of the rocker (26) extends sufficiently to ensure that the projection (34) of the vane (30) is always engagable.
  • Figures 13(a) to (c) represent an inhaler similar to those disclosed in. Figures 1 to.12 in which the triggering mechanism comprises a vane (30) , catch (18) and activator (8) .
  • the rocker of the previous triggering mechanisms is omitted and the catch (18) comprises a long arm (96) which engages the projection (34) on the vane (30).
  • the vane (30) lifts causing the catch (18) to pivot in the direction of the arrows.
  • the catch (18) disengages the activator (8) causing it to move to its dispensing position under the torque provided by spring (90) .
  • the triggering mechanism is reset by closing the cover (4) , reset projection (68) moving the activator (8) back to its restrained position, the activator engaging reset arm (88) on the catch (18) , which in turn engages the projection (34) on the vane (30) with arm (96) , thereby completing the reset cycle.
  • Figure 14 illustrates the application of the triggering assembly of the invention to a pressurised aerosol inhaler of the type disclosed in European Patent No. 147028 and commercially available under the registered trade marks AEROLIN AUTOHALER.
  • Figure 14 shov the dispensing end of the inhaler comprising a housing (100) having a mouthpiece (102) and containing a pressurised aerosol container equipped with a metering valve, generally shown at (104) .
  • the valve stem (106) is retained within a nozzle block (108) .
  • the valve is actuated to dispense a metered dose of medicament by moving the valve stem (106) inwardly relative to the container.
  • the triggering mechanism comprises a vane (110) pivotally mounted at (112) having a projection (114) which engages arm (116) on rocker (118) .
  • the rocker (118) is pivotally mounted at (120) and has a projection (122) engaging arm (124) of catch (126) .
  • Catch (126) comprises a blocking arm (128) which engages activator (130) and a reset arm (132) .
  • a blocking lever (134) is pivotally mounted at (136) and has one end (138) which engages shoulder (140) of the activator (130) and a second end (142) which.abuts the valve ferrule (144).
  • the activator (130) is provided with a reset spring (146).
  • a priming force is applied to the aerosol container in the direction of the arrow in Figure 14(b) , for example by pushing a lever (not shown) on the top of the inhaler which acts to compress a spring against the base of the aerosol container.
  • the priming force exceeds the force on the return spring (146) and movement of the aerosol container is prevented by the blocking lever (134) abutting the valve ferrule, movement of the blocking lever (134) being pa_svented by the-xestrained activator (130) .
  • the activator (130) is thus biased towards its dispensing position under the influence of that part of the priming force which reaches the activator (130) via the blocking lever (134) , which part force exceeds the opposing force from the return spring (146) .
  • the vane (110) starts to lift causing pivotal movement of the rocker (118) and catch (126) in the direction of the arrows.
  • the reset spring (146) causes the activator (130) to pivot towards its restrained position which movement of the activator causes pivotal movement of the blocking lever to its blocking position.
  • the movement of the activator (130) is transferred to the catch (126) and thence to.,the.racker (118) and thence to the vane (110) to complete the reset cycle in a similar manner to the triggering mechanism illustrated in Figures 11 and 12.
  • Figures 15(a) and 15(b) illustrate the triggering and reset sequences of a two component triggering mechanism comprising a vane (150) and activator (154) .
  • the vane (150) is pivoted at (152) and the activator is pivoted at (156) and is biased in the clockwise direction.
  • the activator (154) is held in its restrained position by the blocking action of projection (158) near the end of the vane

Abstract

Dispositif d'inhalation pour l'administration d'un médicament aérosol dans le système respiratoire d'un patient, comprenant un logement (2) définissant une ouverture pour le patient (6) et une entrée d'air. Le logement contient un dispositif permettant d'administrer une dose de médicament aérosol, un médicament de déclenchement de l'inhalation permettant d'activer le dispositif d'administration, et un dispositif de remise à zéro. Le mécanisme de déclenchement comprend un clapet (30) monté de manière à pouvoir pivoter entre une position ouverte et une position fermée, et disposé de sorte que l'inhalation par le patient à travers l'ouverture prévue à cet effet génère un flux d'air provenant de l'entrée d'air et allant en direction de l'ouverture du patient, causant par là un mouvement de pivotement du clapet. Le mouvement d'un élément d'activation (8) mobile entre une position de maintien et une position d'administration entraîne l'administration du médicament par le dispositif d'administration, l'élément d'activation étant incliné dans sa position d'administration.An inhalation device for administering an aerosol medication to the respiratory system of a patient, comprising a housing (2) defining an opening for the patient (6) and an air inlet. The housing contains a device for administering a dose of aerosol medication, an inhalation initiation medication for activating the delivery device, and a reset device. The trigger mechanism comprises a valve (30) mounted so that it can pivot between an open position and a closed position, and arranged so that inhalation by the patient through the opening provided for this purpose generates a flow of air coming from the air inlet and going towards the patient's opening, thereby causing the valve to pivot. The movement of an activating element (8) movable between a holding position and an administration position causes the administration of the medicament by the administration device, the activating element being inclined in its position of administration.

Description

INHALATION DEVICE This invention relates to inhalation activatable devices for the administration of medicaments for inhalation therapy. Inhalation activatable dispensers for use with aerosol container assemblies are known, their general purpose being to afford proper co-ordination of the dispensing of a dose of medicament with the inhalation of the patient thereby allowing the maximum proportion of the dose of medicament to be drawn into the patient's bronchial passages. Examples of such dispensers are described in British Patent Specification Nos. 1,269,554, 1,335,378, 1,392,192 and 2,061,116 and United States Patent Nos. 3,187,748, 3,456,644, 3,456,645, 3,456,646, 3,565,070, 3,598,294, 3,814,297, 3,605,738, 3,732,864, 3,636,949 and 3,789,843 and German Patent No. 3,040,641. European Patent No. 147028 discloses an inhalation activatable dispenser for use with an aerosol container in which a latch mechanism releasing vane is pivotally mounted in an air passage between an aerosol outlet valve and a mouthpiece, which latch mechanism cannot be released if..force to activate the dispenser is not applied before a patient inhales.
The dispenser generally comprises a housing having a mouthpiece and an air passage therethrough terminating at the mouthpiece, the housing being adapted to receive an aerosol container and having a support block with a socket adapted to receive the stem of the valve of the aerosol container and a through orifice communicating between the socket and the air passage, and latch means having parts movable between an engaged position in which movement of the container and the support block toward each other upon the application of a force to bias the container and the support block toward each other is prevented and a release position in which movement of the container and the support block toward each other in response to said force is permitted causing the stem to move to its inner discharge position, the latch means comprising a vane mounted on the housing in the air passageway between the orifice and the mouthpiece for movement toward the mouthpiece under the influence of inhalation through the mouthpiece to release the latch means in which the vane moves toward the mouthpiece from a blocking to a non-blocking position with respect to the passageway in response to inhaling at the mouthpiece and releases the latch means only during the application of said force to bias the container and support block toward each other. Co-pending International Patent Application No.
PCT/US90/02412 (Publication No. O90/13328) discloses a dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that.paα:t__c__les of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow. The dry powder inhaler is capable of delivering multiple, uniform doses of a medicament to a patient. The device is simple to operate and does not require the patient to insert capsules of medicament or rely upon a separate reservoir of medicament in order to load the device for use. The medicament is generally preloaded on an elongate carrier, sections of which are sequentially exposed in the chamber for dispensing the medicament. The elongate carrier is preferably in the form of a tape having an array of depressions or microdimples holding micronised medicament and may be conveniently loaded on a spool (in a similar manner to a photographic film) or in a cassette (in a similar manner to an audio cassette) . A preferred carrier is disclosed in European Patent Publication No. 0455463. The device includes means for advancing the elongate carrier through the chamber to sequentially expose areas of the carrier for release of medicament during inhalation by the patient. The means for advancement may take a variety of forms depending upon the type of elongate carrier and whether the exposed areas of carrier are to be retained within the device. For example, tapes webs and belts may include a series of apertures which are engaged by one or more sprocketed guide wheels or rollers in a similar manner to a camera or printer.
Alternatively, or in addition, the carrier may be wound on a take-up spool, rotation of the spool directly or via a drive belt causing the carrier to advance. The device may also include means for tensioning or otherwise maintaining the exposed area of the carrier within the chamber during inhalation by the patient.
The elongate carrier may be advanced into the chamber prior to inhalation by the patient or the carrier may be advanced into the aerosolisation chamber during inhalation to protect the powdered medicament from premature exposure.
In the .preferred embodiment the elongate carrier is stored in a cassette both before and after exposure. The cassette may comprise one or preferably two spools together with idlers or other rollers and include an exposure frame positioned within the chamber, through which the carrier is advanced. The cassette may be removable to allow the device to be recharged with a new cassette. However, it is not essential for the exposed areas of the carrier to be retained within the device and spent carrier may be advanced to the exterior of the device through a slot in the housing whereupon disposal may be effected by the patient, optionally with the aid of a cutting edge. This arrangement is particularly suitable for a tape carrier which has transverse perforations to facilitate tearing off spent carrier.
The device preferably additionally comprises means for releasing medicament of respirable size from the exposed area of carrier independent of the patients' inspiratory effort. The medicament release means overcomes the binding of the medicament particles to the carrier by mechanical effort e.g. impaction, vibrations, gas flow etc. or electrostatically. The means for releasing medicament from the carrier during inhalation is preferably triggered in response to the patient inhaling in order to avoid the patient having to synchronise inhalation and actuation of the release mechanism. Airflow detection may conveniently be accomplished by.means of a movable vane positioned within the chamber or patient port, motion of the vane causing actuation of the release mechanism. Such a vane may also be constructed to prevent a patient exhaling through the device and/or to prevent exhaled air from reaching the stored carrier thereby avoiding any problems associated with moisture.
The present invention provides an improved triggering mechanism which is suitable for use in such an inhalation device and may also be employed in other dry powder or pressurised aerosol inhalation devices.
According to the present invention there is provided an inhalation device for -administration of aerosolised medicament to the respiratory system of a patient comprising a housing defining a patient port in the form of a mouthpiece or nasal adaptor and an air inlet, the housing containing means for dispensing a dose of aerosolised medicament, an inhalation-activatable triggering mechanism for initiating the dispensing means, and reset means, in which the triggering mechanism comprises a vane mounted for pivotal movement between closed and open positions, the vane being positioned such that inhalation through the patient port generates an air flow from the air inlet to the patient port causing pivotal movement of the vane, and an activator component movable between a restrained position and a dispensing position which movement causes dispensing of medicament from the dispensing means, the activator component being biased towards its dispensing position, the triggering mechanism being constructed and arranged such that: a) when the activator component is in the restrained position and the vane is in the closed position the activator component is held in its restrained position by mechanical blocking action of the vane either directly by the vane or via one or more movable intermediate components whose movements to release the mechanical blocking action are controlled by the. vane, b) pivotal movement of the vane from its closed to its open position removes said mechanical blocking action allowing movement of the activator component to its dispensing position and c) operation of the reset means causes movement of the activator component from its dispensing to its restrained position which movement causes, directly or indirectly via one or more intermediate components, the vane to move from its open or a partially open position to its closed position if the vane is not closed.
Preferably, the activator component is arranged to move pivotally between its restrain-id position and. its dispensing position, but it may alternatively be arranged to move reciprocally, linearly or in some other fashion. The invention provides a triggering mechanism for actuating an inhaler device which obviates the need for handling co-ordination by the patient and actuates at low flow-rates, e.g., 30 litres per minute, within the capabilities of most asthma sufferers. The components of the triggering mechanism are arranged such that they may mechanically interengage during the reset cycle thus by simply returning the activator component to its restrained position it is positively ensured that the other components are returned to their respective positions ready for the next triggering sequence. This arrangement ensures the mechanism will be reset regardless of the orientation of the inhaler device during the reset procedure since it does not rely on gravity to return any of the components to the required position. Furthermore, since the various components interengage during the reset cycle there are no problems associated with synchronisation of different moving parts of the mechanism. The vane is conveniently positioned within the patient port of the inhalation device and may be arranged such that it may be wholly or partially returned from its open to its closed position prior to the reset cycle providing it is then positively engaged by a component of the triggering- mechanism as the. mechanism is reset. This freedom of movement of the vane, which may take place under the influence of gravity should the patient's inhalation falter or which may take place should the patient exhale through the patient port, allows the mouthpiece to be closed by the vane preventing contaminants entering the housing prior to resetting the triggering mechanism. The vane pivot point is ordinarily positioned towards one end of the vane.
The triggering mechanism is particularly suitable for use in the inhalation devices of International
Publication Nos. O90/13327 and WO90/13328. However, the triggering mechanism may readily*-_e- employed in.-other dry powder and pressurised aerosol devices which utilise a biased activator component. In its simplest form the triggering mechanism may simply comprise a vane and activator component. In such an arrangement the vane comprises blocking and reset surfaces positioned at an end of the vane near the pivot point, e.g. by providing a pair of projections or arms on the vane, such that: a) when the activator component is in the restrained position and the vane is in the closed position the blocking surface mechanically engages the activator component preventing movement"of the activator component from its restrained position. b) when the vane is pivoted from its closed to open position the blocking surface is moved out of mechanical engagement with the activator component allowing it to move from the restrained to the dispensing position and c) operation of the reset means to move the activator component from its dispensing to its restrained position causes engagement of the reset surface by the activator component pivoting the vane to its closed position thereby mechanically blocking the activator component in its restrained position.
It is not always convenient to position the activator component close to the vane in some inhalation devices and it may be convenient to employ one or more intermediate components between the vane and activator.to allow separation thereof.
For example, a three component triggering mechanism may comprise a vane, catch and activator component, the catch being pivotally mounted for movement between a blocking position in which it mechanically blocks movement of the activator component from its restrained position and a release position in which it allows movement of the activator component to its dispensing position, the catch and vane each having a respective engagable end which allows movement transfer therebetween, the catch having a second end having a blocking -surface which engages the activator component in its restrained position and a reset surface which is engaged by the activator component during movement from its dispensing to its restrained position under the influence of the reset means thereby causing movement of the catch to its blocking position and vane to its closed position.
A four component triggering mechanism may comprise a vane, rocker, catch and activator component, the catch being pivotally mounted for movement between a blocking position in which it mechanically blocks movement of the activator component from its restrained position and a release position in which it allows movement of the activator component to its.dispensing position, the rocker being mounted for pivotal movement and having one end engagable with one end of the vane to allow movement transfer therebetween and a second end engagable with the catch to allow movement transfer therebetween, the catch having a blocking surface which engages the activator component in its restrained position and a reset surface which is engaged by the activator component during movement from its dispensing to its restrained position under the influence of the reset means thereby causing movement of the catch to its blocking position, and movement of the rocker and thereby movement of the vane to its closed position.
Whilst the use of three or four component triggering mechanisms may impart,-additional friction into the system at the pivot points and contacting surfaces, the friction may readily be overcome by positioning the pivot points to gain a mechanical advantage on the lever principle. The use of such a multi-component triggering mechanism also readily allows the triggering mechanism to be fitted into available areas in the inhalation device since it does not require the presence of a long straight lever, and the pivot points of the components need not be arranged linearly. The reset means for the triggering mechanism preferably acts directly on the activator component and moves it against its biasing;,means back to its restrained position. The reset means may conveniently take the form of a projection on a hinged cover for the mouthpiece such that the inhalation device is reset when the cover is closed after the patient has used the device.
The invention will now be described with reference to the accompanying drawings in which:
Figures 1 to 10 represent a cross-section through an inhaler in accordance with the invention illustrating the various stages of operation,
Figures 11 and 12 represent cross-sections through a second inhaler in accordance with the invention,
Figures 13(a) to 13(c) represent diagrams of a further triggering mechanism for use in the invention, Figures 14(a) to 14(c) represent partial cross- sections of an inhaler in accordance with the invention having a pressurised aerosol container, and
Figures 15(a) and 15(b) represent diagrams of the triggering and reset cycles of a two component triggering mechanism.
The inhaler of Figures 1 to 10 is of a type disclosed in International Publication No. WO90/13328, the medicament being carried on a tape contained within a removable cassette.
In Figures 1 to 10 like numerals represent like parts.
Figures l to 5 of the accompanying drawings illustrate a section- through an inhaler with the cassette removed. The inhaler comprises a housing (2) , a movable cover (4) and a patient port (6) in the form of a mouthpiece.
The means for releasing medicament is in the form of an activator generally shown at (8) which comprises an impactor head (11*) for striking the elongate carrier, the impactor head being attached to a stem (12) which is mounted for movement and rotation about point (14) . An impactor spring (15) provides a bias to move the activator to its dispensing position and is secured to the stem (12) and has a roller (16) at one end thereof. The activator is held in a restrained position by. a catch (18) which has a blocking surface (20) in the form of a roller engaging the impactor head (10) of the activator. The catch (18) is mounted for pivotal movement about point (22) and has an arm (24) engaged by rocker (26) . The rocker (26) is mounted for pivotal movement about point (28) . The means for detecting patient inspiration comprises a vane (30) positioned within the mouthpiece (6) . The vane (30) is mounted for pivotal movement about point (32) and includes a projection (34) which engages the surface (35) of the rocker (26) .
Figure 1 shows the device with the cover closed and the components restrained. Opening of the cover (Figure 2) causes pivotal movement of cam (36) acting on roller (16) thereby imparting tension to the impactor spring (15) . Movement of the impactor head (10) is prevented by the catch (18) . When the patient inhales through the mouthpiece the vane (30) pivots as shown in the direction of the arrow. Pivotal movement of the vane (30) in turn causes pivotal movement of the rocker (26) and pivotal movement of the catch (18) as shown in the direction of the arrows, causing the roller (20) to lift clear of the impactor head (10) thereby allowing the activator to move in the direction of the arrow (A) (Figure 3) and the impactor head (10) to strike the elongate carrier.
The vane (30) is lifted to the top of the passage of the mouthpiece during inhalation. The end of the vane (30) includes a curved portion (31) which extends in to the potential pathway for exhaled air, thereby ensuring the vane (30) will snap shut immediately, should the patient exhale through the mouthpiece (6) (Figure 4) . Alternatively, the vane may be straight, but a curve (not shown) in the roof of the mouthpiece may ensure that the end of the vane extends into the potential pathway for exhaled air.
Figure 5 illustrates drive gear (40) which is connected to the cover (4) for rotation during opening of the cover (4) . The drive gear (40) drives idler gear (42).
Referring to Figure 6,. the cassette generally shown at (44) , containing the elongate carrier, is inserted in the device and may be retained by a pivoted catch (46) . The cassette (44) comprises a housing (48) (Figure 7) and contains spools (50 and 52) , the elongate carrier (54) being wound on spool (50) and extending via rollers (56 and 58) to spool (52) . A drive belt (60) passes round idler rollers (62) and contacts the carrier (54) on spool (50) , throughout its entire length around the rollers (56 and 58) and on spool (52) . The drive belt also extends around driven roller (64) .
When the cover (4) is opened the gear train (40) is rotated causing rotation of idler gear "(42) and driven roller (54) , thereby causing movement of the drive belt and advancement of the tape (54) . The driven roller (64) includes a non-return ratchet generally shown at (66) and also includes a similar drive ratchet (not shown) mounted lower on the shaft. --
Figure 8 illustrates the inhaler during inhalation through the mouthpiece. The impactor head (10) comprises a raised impactor surface (11) which strikes the drive belt (60) which is in contact with the tape (54) thereby imparting sufficient energy to the tape (54) to release the powdered medicament in to the air stream formed by the patient's inhalation.
Figure 9 illustrates the movement of the various components during the reset cycle which is achieved by closing of the cover.. The activator (8.) is moved to its restrained position by reset projection (68) mounted on the inside of the cover. As the activator (8) is returned towards its restrained position by the reset projection (68) it engages the reset surface (78) of the catch (18) causing pivotal movement of the catch (18) in the direction of the arrows. The arm (24) of the catch (18) engages the rocker (26) causing pivotal movement of the rocker (26) in the direction of the arrows. Movement of the rocker (26) causes engagement between the surface (35) and the projection (34) on the vane (30) . The point during the reset cycle at which this engagement will "'-occur depends upon the position of the vane when the reset cycle is commenced. If the vane is in its opened position the rocker will immediately engage the vane but if the vane is in the closed position, e.g. if the patient has exhaled through the mouthpiece, engagement of the rocker and vane will not occur until the end of the reset cycle. Engagement will occur part way through the reset cycle if the vane is in an intermediate position. The mouthpiece (6) may be integrally formed with the housing or may be removable for cleaning purposes. Figure 10 of the drawings illustrates a removable mouthpiece (6) . The mouthpiece comprises a peg (70) which is engaged within slot (72) in the housing of the inhaler. The peg (70) may be disengaged from the slot for complete removal of the mouthpiece (6) . The mouthpiece (6) additionally comprises a retaining clip (74) which engages with the sides of aperture (76) formed on the housing of the inhaler. Figures 11 and 12 illustrate an inhaler similar to that of Figures 1 to 10 having a modified triggering mechanism. Like numerals in these Figures represent like components in Figures 1 to 10. The rocker (26) comprises an arm (82) which engages the arm (24) of the catch (18) during the triggering and reset cycles. The catch comprises a blocking arm (86) which engages the activator (8) in its restrained position and reset arm (88) which engages the activator (8) during the reset cycle. The activator (8) is biased towards its dispensing position by spring (90) .
Figure 11 shows the inhaler at the onset of inhalation through the mouthpiece (6) with the vane (30) lifting causing pivotal movement of the rocker (26) and catch (18) in the direction of the arrows.
Figure 12 shows the inhaler dispensing the medicament; the vane (30) has lifted to its open position causing sufficient movement of the rocker (26) and catch (18) such that the blocking arm (86) of the catch (18) disengages the activator (8) allowing the activator (8) to pivot to its dispensing position under the influence of spring- (90) . The impactcr head (92) carried on the activator (8) strikes the elongate carrier to dispense powdered medicament into the airflow for inhalation by the patient.
When the cover is closed, reset projection (68) pushes the activator (8) back to its restrained position thereby tensioning spring (90) . During the reset cycle the activator engages reset arm (88) of the catch (18) causing pivotal movement of the catch (18) . The arm (24) of the catch (18) engages arm (82) of the rocker (26) causing pivotal movement of the rocker (26) . Surface (35) of the rocker engages projection (34) of the vane (30) to complete vane closure thereby resetting the triggering mechanism. Upon complete closure of the cover (4) the reset projection preferably moves out of contact with the activator (8) and is positioned within recess (94) formed in the activator (8) to ensure that the activator (8) is restrained by the catch (18) with no strain on the cover (4) . This arrangement also allows the cover (4) to be fully closed.
In the inhalation devices illustrated by Figures 1 to 12, the rocker (26) is arranged such that it is unable to rotate so far clockwise as to no longer be engagable by the catch (18) and such that the surface (35) of the rocker (26) extends sufficiently to ensure that the projection (34) of the vane (30) is always engagable.
Figures 13(a) to (c) represent an inhaler similar to those disclosed in. Figures 1 to.12 in which the triggering mechanism comprises a vane (30) , catch (18) and activator (8) . The rocker of the previous triggering mechanisms is omitted and the catch (18) comprises a long arm (96) which engages the projection (34) on the vane (30). As inhalation commences (Figure 13(b)) the vane (30) lifts causing the catch (18) to pivot in the direction of the arrows. When the vane (30) lifts to its open position (Figure 13(c)) the catch (18) disengages the activator (8) causing it to move to its dispensing position under the torque provided by spring (90) . The triggering mechanism is reset by closing the cover (4) , reset projection (68) moving the activator (8) back to its restrained position, the activator engaging reset arm (88) on the catch (18) , which in turn engages the projection (34) on the vane (30) with arm (96) , thereby completing the reset cycle.
Figure 14 illustrates the application of the triggering assembly of the invention to a pressurised aerosol inhaler of the type disclosed in European Patent No. 147028 and commercially available under the registered trade marks AEROLIN AUTOHALER. Figure 14 shov the dispensing end of the inhaler comprising a housing (100) having a mouthpiece (102) and containing a pressurised aerosol container equipped with a metering valve, generally shown at (104) . The valve stem (106) is retained within a nozzle block (108) . The valve is actuated to dispense a metered dose of medicament by moving the valve stem (106) inwardly relative to the container. The triggering mechanism comprises a vane (110) pivotally mounted at (112) having a projection (114) which engages arm (116) on rocker (118) . The rocker (118) is pivotally mounted at (120) and has a projection (122) engaging arm (124) of catch (126) . Catch (126) comprises a blocking arm (128) which engages activator (130) and a reset arm (132) . A blocking lever (134) is pivotally mounted at (136) and has one end (138) which engages shoulder (140) of the activator (130) and a second end (142) which.abuts the valve ferrule (144). The activator (130) is provided with a reset spring (146).
In use a priming force is applied to the aerosol container in the direction of the arrow in Figure 14(b) , for example by pushing a lever (not shown) on the top of the inhaler which acts to compress a spring against the base of the aerosol container.
The priming force exceeds the force on the return spring (146) and movement of the aerosol container is prevented by the blocking lever (134) abutting the valve ferrule, movement of the blocking lever (134) being pa_svented by the-xestrained activator (130) . The activator (130) is thus biased towards its dispensing position under the influence of that part of the priming force which reaches the activator (130) via the blocking lever (134) , which part force exceeds the opposing force from the return spring (146) . As the patient begins to inhale through the mouthpiece (102) (Figure 14(b)) the vane (110) starts to lift causing pivotal movement of the rocker (118) and catch (126) in the direction of the arrows. When the vane (110) is fully open the movement transferred via the rocker (118) to the catch (126) is sufficient to disengage the catch (126) from the activator. The priming force transmitted through the aerosol container, valve ferrule and blocking lever (134) to the activator (130) is sufficient for the activator (130) to pivot as shown in Figure 14(c) which allows pivotal movement of the blocking lever (134) thereby enabling downward movement of the aerosol container firing the valve to dispense a dose of medicament. When the dose has been administered the priming force is removed and the aeroc l container is raised under the influence of the ii.£,«_rnal spring in the valve (not shown) . The reset spring (146) causes the activator (130) to pivot towards its restrained position which movement of the activator causes pivotal movement of the blocking lever to its blocking position. The movement of the activator (130) is transferred to the catch (126) and thence to.,the.racker (118) and thence to the vane (110) to complete the reset cycle in a similar manner to the triggering mechanism illustrated in Figures 11 and 12. Figures 15(a) and 15(b) illustrate the triggering and reset sequences of a two component triggering mechanism comprising a vane (150) and activator (154) . The vane (150) is pivoted at (152) and the activator is pivoted at (156) and is biased in the clockwise direction. When the vane (150) is closed the activator (154) is held in its restrained position by the blocking action of projection (158) near the end of the vane
(150) . As the vane (150) is pivoted under the influence of -airflow, the projection (158) disengages. the activator (154) allowing it to move to its dispensing position.
During the reset cycle (Figure 15(b)) the activator (154) is urged to its restrained position causing it to engage a reset surface (160) on the end of the vane (152) pivoting the vane to its closed position thereby retaining the activator in its restrained position.

Claims

1. An inhalation device for administration of aerosolised medicament to the respiratory system of a patient comprising a housing defining a patient port in the form of a mouthpiece or nasal adaptor and an air inlet, the housing containing means for dispensing a dose of aerosolised medicament, an inhalation-activatable triggering mechanism for initiating the dispensing means, and reset means, in which the triggering mechanism comprises a vane,mounted for pivotal movement between closed and open positions, the vane being positioned such that inhalation through the patient port generates an air flow from the air inlet to the patient port causing pivotal movement of the vane, and an activator component movable between a restrained position and a dispensing position which movement causes dispensing of medicament from the dispensing means, the activator component being biased towards its dispensing position, the triggering mechanism being constructed and arranged such that: a) when the activator component is in the restrained position and the vane is in the closed position the activator component is held in.its restrained position by mechanical blocking action of the vane either directly by the vane or via one or more movable intermediate components whose movements to release the mechanical blocking action are controlled by the vane, b) pivotal movement of the vane from its closed to its open position removes said mechanical blocking action allowing movement of the activator component to its dispensing position and c) operation of the reset means causes movement of the activator component from its dispensing to its restrained position which movement causes, directly or indirectly via one or more intermediate components, the vane to move from its open or a partially open position to its closed position if the vane is not closed.
2. An inhalation device as claimed in Claim 1 in which the vane comprises blocking and reset surfaces positioned at an end of the vane towards the pivot point such that: a) when the activator component is in the restrained position and the vane is in the closed position the blocking surface mechanically engages the activator component preventing movement of the activator component from its restrained position. b) when the vane is pivoted from its closed to open position the blocking surface is moved.out of mechanical engagement with the activator component allowing it to move from the restrained to dispensing position and c) operation of the reset means to move the activator component from its dispensing to restrained position causes engagement of the reset surface by the activator component pivoting the vane to its closed position thereby mechanically blocking the activator component in its restrained position.
3. An inhalation device as claimed in Claim 1 in which the triggering mechanism comprises the vane, a catch and the activator component, the catch being pivotally mounted for movement between a blocking.:position in which it mechanically blocks movement of the activator component from its restrained position and a release position in which it allows movement of the activator component to its dispensing position, the catch and vane each having a respective engagable end which allows movement transfer therebetween, the catch having a second end having a blocking surface which engages the activator component in its restrained position and a reset surface which is engaged by the activator component during movement from its dispensing to its restrained position under the influence of the reset means thereby causing movement of the catch to its blocking position and vane to its closed position.
4. An inhalation device as claimed in Claim 1 in which the triggering mechanism comprises the vane, a rocker, a catch and the activator component, the catch being pivotally mounted for movement between a blocking position in which it mechanically blocks movement of the activator component from its restrained position and a release position in which it allows movement of the activator component to its dispensing position, the rocker being mounted for pivotal movement, the rocker having one end engagable with one end of the vane to allow movement transfer therebetween and a second end engagable with the catch to allow movement transfer therebetween, the catch having a blocking surface which engages the activator component in its restrained position and a reset surface which is engaged by the activator component during movement from its dispensing to restrained position under the influence of the reset means thereby causing movement of the catch to its blocking position, and movement of the rocker and thereby movement of the vane to its closed position.
5. An inhalation device as claimed in any preceding Claim in which the vane is positioned within the patient port.
6. An inhalation device as claimed in any preceding
Claim in which the vane is free to pivot from its open to closed position without operation of the reset- eans.
7. An inhalation device as claimed in any preceding Claim additionally comprising a cover movable between open and closed positions, such that closure of the cover causes movement of the activator component from its dispensing to its restrained position.
8. An inhalation device as claimed in any preceding Claim comprising a reservoir of medicament in the form of a dry powder and means to dispense a dose of said medicament.
9. An inhalation device as claimed in Claim 8 in which the dry powder is carried on an elongate carrier and the dispenser means comprises means to strike a portion of the elongate carrier to dislodge dry powder from the elongate carrier when the activator component moves to its dispensing position.
10. An inhalation device as claimed in Claim 9 in which the elongate carrier is wound on a spool, hub or reel within a cassette and the inhalation device comprises means to advance the carrier to sequentially expose areas for dispensing medicament therefrom.
11. An inhalation device as claimed in any one of Claims 1 to 7 which comprises a pressurised aerosol container equipped with a metered dose dispensing valve.
12. An inhalation device as claimed in Claim 11 which comprises means to apply a priming force to the dispensing valve and in which the triggering mechanism exerts a blocking action preventing actuation of the dispensing valve, the blocking action being removed when the activator component moves to its dispensing position.
EP91919636A 1990-11-14 1991-11-12 Inhalation device Expired - Lifetime EP0557333B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909024760A GB9024760D0 (en) 1990-11-14 1990-11-14 Inhalation device and medicament carrier
GB9024760 1990-11-14
PCT/GB1991/001983 WO1992008509A1 (en) 1990-11-14 1991-11-12 Inhalation device

Publications (2)

Publication Number Publication Date
EP0557333A1 true EP0557333A1 (en) 1993-09-01
EP0557333B1 EP0557333B1 (en) 1996-09-11

Family

ID=10685367

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91919636A Expired - Lifetime EP0557333B1 (en) 1990-11-14 1991-11-12 Inhalation device

Country Status (9)

Country Link
US (1) US5408994A (en)
EP (1) EP0557333B1 (en)
JP (1) JPH06502095A (en)
AU (1) AU655610B2 (en)
CA (1) CA2095923A1 (en)
DE (1) DE69122118T2 (en)
GB (1) GB9024760D0 (en)
NZ (1) NZ240562A (en)
WO (1) WO1992008509A1 (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5469843A (en) * 1991-11-12 1995-11-28 Minnesota Mining And Manufacturing Company Inhalation device
GB9123953D0 (en) * 1991-11-12 1992-01-02 Minnesota Mining & Mfg Inhalation device
SE9203570D0 (en) * 1992-11-27 1992-11-27 Astra Ab INHALES FOR MULTIPLE USE
WO1994023772A2 (en) * 1993-04-06 1994-10-27 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
GB9314614D0 (en) * 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
US6672304B1 (en) * 1995-06-08 2004-01-06 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIs)
US6357442B1 (en) * 1995-06-08 2002-03-19 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIS)
US5826571A (en) * 1995-06-08 1998-10-27 Innovative Devices, Llc Device for use with metered dose inhalers (MDIS)
US20040237961A1 (en) * 1995-06-08 2004-12-02 Snow John Medlin Inhalation actuated device for use with metered dose inhalers (MDIs)
US6209538B1 (en) * 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5823183A (en) * 1995-08-02 1998-10-20 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5988163A (en) * 1995-08-02 1999-11-23 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of delivery of medicament
US5724986A (en) * 1995-11-06 1998-03-10 Jones Medical Instrument Co. Casing and spirometer for metered dose inhaler
US6006747A (en) * 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
WO1998052634A1 (en) * 1997-05-23 1998-11-26 Pa Knowledge Limited Inhaler mechanism
SI20363A (en) * 1998-01-30 2001-04-30 Ig Spruehtechnik Gmbh & Co.Kg Inhalation apparatus for powder medications
SK13632000A3 (en) 1998-03-16 2001-03-12 Inhale Therapeutic Systems, Inc. Aerosolized active agent delivery
SE9801077D0 (en) * 1998-03-27 1998-03-27 Shl Medical Ab Inhaler
SE9801078D0 (en) 1998-03-27 1998-03-27 Shl Medical Ab Inhaler
UA73924C2 (en) * 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
GB9825118D0 (en) * 1998-11-16 1999-01-13 Minnesota Mining & Mfg Breath-actuated aerosol dispensers
GB2344535B (en) * 1998-12-11 2000-10-18 Bespak Plc Inhalation apparatus
US6223744B1 (en) 1999-03-16 2001-05-01 Multi-Vet Ltd. Wearable aerosol delivery apparatus
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DK2280020T3 (en) 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US6606992B1 (en) * 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
SE9902672D0 (en) * 1999-07-12 1999-07-12 Astra Ab Delivery device
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
JP2003513718A (en) * 1999-11-10 2003-04-15 イノベーティブ・ディバイシィーズ・エルエルシー Inhalation actuator for use with a metered dose inhaler (MDI)
US7080642B2 (en) * 1999-12-22 2006-07-25 3M Innovative Properties Company Refillable device with counting means
GB9930602D0 (en) * 1999-12-24 2000-02-16 Glaxo Group Ltd Inhalation device
US7171965B2 (en) * 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6581590B1 (en) 2000-03-21 2003-06-24 Iep Pharmaceutical Devices Inc. Inhalation actuated device
US6328035B1 (en) 2000-05-09 2001-12-11 Iep Pharmaceutical Devices Inc. Pneumatic breath actuated inhaler
US6948494B1 (en) * 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
SE517229C2 (en) * 2000-09-25 2002-05-14 Microdrug Ag Continuous dry powder inhaler
EP1320397B1 (en) * 2000-09-29 2010-01-20 Pfizer Limited Medical Inhalation-Device
SE0100034D0 (en) * 2001-01-04 2001-01-04 Astrazeneca Ab A delivery device
GB0109001D0 (en) * 2001-04-10 2001-05-30 Glaxo Group Ltd Dispenser
JP4261351B2 (en) 2001-09-19 2009-04-30 アドヴェント ファーマセウティカルズ プロプライエタリー リミテッド Inhaler
US20030168057A1 (en) * 2001-12-14 2003-09-11 Inhale Therapeutic Systems, Inc. Electronically controllable aerosol delivery
GB0204829D0 (en) * 2002-03-01 2002-04-17 Glaxo Group Ltd A fluid dispensing device
JP4681231B2 (en) 2002-03-20 2011-05-11 マンカインド コーポレイション Inhaler
GB2401321B (en) * 2002-03-22 2005-12-07 Clinical Designs Ltd Can fixture
SE525027C2 (en) * 2002-04-12 2004-11-16 Microdrug Ag Device comprising a powder air grinder
SE524957C2 (en) * 2002-04-12 2004-11-02 Microdrug Ag Method for dividing and distributing in air of dry powder drug
SE524990C2 (en) * 2002-04-12 2004-11-09 Microdrug Ag Preparation of therapeutic dry powder and method for splitting and spreading in the air of medical powder
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US7185651B2 (en) * 2002-06-18 2007-03-06 Nektar Therapeutics Flow regulator for aerosol drug delivery and methods
EP1558317A2 (en) * 2002-11-04 2005-08-03 Cambridge Consultants Limited Pressurised inhalers
GB2398254B (en) * 2003-02-11 2005-12-07 Bespak Plc Dispensing Apparatus
GB0304000D0 (en) * 2003-02-21 2003-03-26 Clinical Designs Ltd Dispenser
DE10352277A1 (en) * 2003-11-08 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg powder inhaler
GB0327112D0 (en) * 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0328859D0 (en) * 2003-12-12 2004-01-14 Clinical Designs Ltd Dispenser and counter
US20050183718A1 (en) * 2004-02-24 2005-08-25 Boehringer Ingelheim International Gmbh Nebulizer
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
BRPI0514263B8 (en) 2004-08-20 2021-05-25 Mannkind Corp method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
GB0425518D0 (en) 2004-11-19 2004-12-22 Clinical Designs Ltd Substance source
WO2006062449A1 (en) * 2004-12-10 2006-06-15 Ernst Hörlins Ingenjörsbyra AB Breath actuated dose inhaler
GB0428204D0 (en) * 2004-12-23 2005-01-26 Clinical Designs Ltd Medicament container
US7219664B2 (en) * 2005-04-28 2007-05-22 Kos Life Sciences, Inc. Breath actuated inhaler
GB0518400D0 (en) 2005-09-09 2005-10-19 Clinical Designs Ltd Dispenser
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
GB2433207B (en) * 2006-02-21 2009-01-07 Jianhe Li Active suction actuated inhalers with timing devices
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
AU2007224178B2 (en) * 2006-03-03 2013-03-07 Stc.Unm Dry powder inhaler with aeroelastic dispersion mechanism
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
HUE034380T2 (en) 2007-04-30 2018-02-28 Sun Pharma Advanced Res Co Ltd Inhalation device
JP5570996B2 (en) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド Delivery of aerosolizable foodstuffs
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
DK2288401T3 (en) * 2008-05-07 2018-10-29 Map Pharmaceuticals Inc DOSAGE STANDS AND LOCKING MECHANISM
FR2931137B1 (en) * 2008-05-13 2012-03-30 Valois Sas DEVICE FOR DISPENSING FLUID PRODUCT
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2982550C (en) 2008-06-13 2020-08-25 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (en) 2008-06-20 2013-12-11 曼金德公司 An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
ES2579902T3 (en) 2008-10-08 2016-08-17 Astrazeneca Ab Inhalation device to administer a medication
JP5512686B2 (en) * 2008-10-08 2014-06-04 アストラゼネカ・アクチエボラーグ Breath-actuated inhaler
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
GB0904040D0 (en) 2009-03-10 2009-04-22 Euro Celtique Sa Counter
GB0904059D0 (en) 2009-03-10 2009-04-22 Euro Celtique Sa Counter
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
EP2414560B1 (en) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Method for coating a surface of a component
JP5763053B2 (en) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Adapter, inhaler and atomizer
US9125999B2 (en) 2009-05-18 2015-09-08 Adamis Pharmaceuticals Corporation Dry powder inhaler dose counters
BRPI1009072B1 (en) 2009-05-18 2021-06-22 Adamis Pharmaceuticals Corporation DEVICE FOR DRY POWDER INHALATION AND DEVICE FOR DRY POWDER STORAGE
ES2943333T3 (en) 2009-06-12 2023-06-12 Mannkind Corp Diketopiperazine microparticles with defined surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
EP2498848A2 (en) 2009-11-12 2012-09-19 Stc.Unm Dry powder inhaler with flutter dispersion member
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EA026241B1 (en) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
CN103826988B (en) 2011-04-01 2016-03-09 曼金德公司 For the blister package of pharmaceutical kit
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013059631A1 (en) 2011-10-21 2013-04-25 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
JP6018640B2 (en) 2011-10-24 2016-11-02 マンカインド コーポレイション Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition
JP6181072B2 (en) * 2011-12-16 2017-08-16 サノフィ・ソシエテ・アノニム Device for administering powdered drugs to patients by inhalation
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10370183B2 (en) 2012-07-19 2019-08-06 Adamis Pharmaceuticals Corporation Powder feeding apparatus
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102391750B1 (en) 2013-03-15 2022-04-28 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
CN105451716A (en) 2013-07-18 2016-03-30 曼金德公司 Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
ES2836977T3 (en) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizer
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
JP2016530030A (en) 2013-09-04 2016-09-29 スリーエム イノベイティブ プロパティズ カンパニー Dry powder inhaler and method
PT3052169T (en) 2013-10-01 2018-10-25 Novartis Ag Blister track inhaler device having a separate end path
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
PL3139979T3 (en) 2014-05-07 2023-12-27 Boehringer Ingelheim International Gmbh Unit, nebulizer and method
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
MX2016014403A (en) 2014-05-07 2017-01-20 Boehringer Ingelheim Int Container, indicator device, and nebulizer.
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN107427650A (en) 2015-01-14 2017-12-01 瑞必治公司 Powder process for dispersing and device
DE202017102334U1 (en) * 2016-08-25 2017-11-29 Alfred Von Schuckmann Device for inhaling powdery substances

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3456644A (en) * 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
US3456645A (en) * 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
US3565070A (en) * 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
BE758834A (en) * 1969-11-13 1971-05-12 Riker Laboratoires Inc AEROSOL DISPENSER ACTIVATED BY INHALATION
GB1383761A (en) * 1971-02-25 1974-02-12 Woodcraft Dc Inhalation device for use with an aerosol container
GB8328808D0 (en) * 1983-10-28 1983-11-30 Riker Laboratories Inc Inhalation responsive dispensers
US4803978A (en) * 1985-08-09 1989-02-14 Johnson Iv John J Apparatus for actuating an inhaler
US5031610A (en) * 1987-05-12 1991-07-16 Glaxo Inc. Inhalation device
US5119806A (en) * 1987-05-12 1992-06-09 Glaxo Inc. Inhalation device
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9208509A1 *

Also Published As

Publication number Publication date
EP0557333B1 (en) 1996-09-11
AU8873391A (en) 1992-06-11
JPH06502095A (en) 1994-03-10
GB9024760D0 (en) 1991-01-02
AU655610B2 (en) 1995-01-05
NZ240562A (en) 1994-12-22
DE69122118T2 (en) 1997-02-13
CA2095923A1 (en) 1992-05-15
US5408994A (en) 1995-04-25
DE69122118D1 (en) 1996-10-17
WO1992008509A1 (en) 1992-05-29

Similar Documents

Publication Publication Date Title
AU655610B2 (en) Inhalation device
EP0414536B1 (en) Inhaler
US6439227B1 (en) Breath-actuation
US7434579B2 (en) Breath actuated dry powder inhaler and tape dose strip
AU727338B2 (en) Aerosol dispensing device
US5619984A (en) Dry powder inhalation device having a powder-loaded elongate carrier
FI82607C (en) Activated dosing device by inhalation
EP0634184B1 (en) Dry powder inhalers
CA2297024C (en) Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5921237A (en) Dry powder inhaler
ES2243277T3 (en) INHALER.
US11167097B2 (en) Dry powder inhaler and inhalation actuated mechanism thereof
FI94593C (en) The inhaler
JP2004508903A (en) Continuous dry powder inhaler
JPH0685802B2 (en) Inhaler administration device
JP4723785B2 (en) Powder inhaler
CA2848024A1 (en) Inhaler

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930503

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RBV Designated contracting states (corrected)

Designated state(s): BE CH DE DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 19950517

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE DK ES FR GB IT LI NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960911

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960911

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19960911

Ref country code: DK

Effective date: 19960911

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960911

Ref country code: BE

Effective date: 19960911

REF Corresponds to:

Ref document number: 69122118

Country of ref document: DE

Date of ref document: 19961017

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: ING. C. GREGORJ S.P.A.

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19981020

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19981021

Year of fee payment: 8

Ref country code: GB

Payment date: 19981021

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19981022

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991113

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19991112

EUG Se: european patent has lapsed

Ref document number: 91919636.0

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000901

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051112